Liver Cirrhosis Market
The Liver Cirrhosis market is witnessing substantial momentum as healthcare systems worldwide grapple with the rising burden of chronic liver disease. The Liver Cirrhosis market size in the 7 Major Markets (7MM) – comprising the United States, EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan – was valued at nearly USD 3,100 million in 2023, and is anticipated to grow at a significant CAGR during the forecast period from 2024 to 2034.
Liver cirrhosis is a chronic and progressive liver disease characterized by the replacement of healthy liver tissue with scar tissue, with an estimated approximately 3,390 thousand diagnosed prevalent population in 2023 across the 7MM. The disease represents a formidable clinical challenge, often progressing silently until severe complications emerge, making timely diagnosis and effective intervention critically important.
Among the 7MM, the United States holds the highest burden of liver cirrhosis, accounting for approximately 61% of all cases in 2023, followed by Japan, Germany, and Italy. According to DelveInsight estimates, this disproportionate share reflects the high prevalence of key etiological drivers including alcohol-related liver disease (ALD), metabolic dysfunction-associated steatohepatitis (MASH), and chronic viral hepatitis in the American population.
The market size of liver cirrhosis is influenced by a multitude of factors including the availability of pharmaceutical and treatment options, disease prevalence, advances in therapeutic development, healthcare infrastructure quality, and reimbursement frameworks. In 2023, the US alone contributed approximately USD 2,180 million to the global liver cirrhosis market, underscoring its dominant position. The Liver Cirrhosis market in Japan was valued at nearly USD 361 million in 2023, accounting for approximately 12% of the total 7MM market, with further growth expected through 2034.
The total market size is projected to surge during the forecast period, driven by the anticipated entry of several emerging therapies, including Efruxifermin (EFX) and Belapectin, both of which are poised to transform the treatment landscape significantly.
A landmark step in advancing scientific understanding of this disease was recently announced as Newcastle University, the University of Edinburgh, and Boehringer Ingelheim unveiled the most extensive clinical study ever conducted into liver cirrhosis worldwide – the ADVANCE (Accelerating Discovery: Actionable NASH Cirrhosis Endpoints) study. This observational study will enroll the largest number of patients ever included in such research, providing deep insights into liver health and identifying translational biomarkers to accelerate the development of future therapies for MASH cirrhosis.
A key epidemiological finding from Liver Cirrhosis market research confirms that Alcoholic Liver Disease (ALD) contributes the highest number of liver cirrhosis cases across the 7MM, reflecting the widespread impact of prolonged and excessive alcohol consumption, which triggers inflammation, fibrosis, and ultimately cirrhosis.
Liver Cirrhosis Treatment Market
Liver Cirrhosis Overview
Cirrhosis represents the histological development of regenerative nodules surrounded by fibrous bands in response to chronic liver injury, culminating in portal hypertension and end-stage liver disease. In this advanced stage, healthy liver tissue is permanently replaced by scar tissue, which progressively impairs liver function. The condition presents with symptoms such as fatigue and severe skin itching, though these often remain absent until the liver sustains substantial damage. Primary causes include alcoholic liver disease, nonalcoholic fatty liver disease, chronic hepatitis C, and chronic hepatitis B.
Liver Cirrhosis Diagnosis
Prominent organizations – including the European Association for the Study of the Liver (EASL), the Japanese Society of Gastroenterology (JSGE), and the American Association for the Study of Liver Diseases (AASLD) – have established diagnostic criteria for liver cirrhosis. Most patients in early-stage cirrhosis remain asymptomatic, with the condition frequently identified incidentally during routine blood tests or medical checkups. Laboratory investigations and imaging tests typically support diagnosis, while liver biopsy remains the gold-standard confirmatory tool – albeit an invasive procedure that many patients find distressing.
When visible symptoms such as jaundice appear, the disease has typically progressed to an irreversible end stage, leaving liver transplantation as the sole curative option. Early detection therefore holds enormous clinical significance, allowing for timely interventions such as alcohol cessation programs, antiviral therapies, and weight management strategies.
Among the most pressing Liver Cirrhosis market trends is the growing demand for improved early-detection tools. There is a critical need for:
- Noninvasive biomarkers capable of identifying cirrhosis before symptom onset
- Accurate diagnostic tests for monitoring disease progression and treatment response
- Biomarker-driven patient stratification to support more effective clinical trial designs
- Tools that enable healthcare providers to deliver early interventions to at-risk but asymptomatic individuals
Current standard diagnostics – including imaging and liver function blood tests – lack sensitivity for detecting early-stage disease, reinforcing the urgency of developing more reliable and accessible biomarkers.
Liver Cirrhosis Treatment
Treatment for cirrhosis is largely targeted at underlying causes and symptomatic management, as the condition itself is generally incurable once established. Current therapeutic approaches include:
- Treating the underlying etiology – such as antiviral therapy for hepatitis B or C infection, or phlebotomy for hemochromatosis-related iron overload
- Dietary and lifestyle modifications – including a low-fat, high-protein diet coupled with regular physical activity to prevent malnutrition and muscle loss
- Management of complications – including ascites, hepatic encephalopathy, and variceal bleeding through hemodialysis, IV antibiotics, banding procedures, and pharmacological interventions
Patients with decompensated cirrhosis face a particularly high burden, requiring intensive supportive care, hospitalization, and complex treatment regimens. Existing therapies for cirrhosis-related complications carry significant side effects and are often expensive, highlighting an enormous unmet need.
Liver transplantation remains the most definitive intervention for liver cirrhosis but is limited by the severe shortage of donor organs – approximately 30% of patients on transplant waiting lists die before receiving a transplant. This critical gap underscores the urgent need for novel, affordable, and effective pharmacological therapies.
Liver Cirrhosis Epidemiology
Grounded in a patient-based modeling approach, the epidemiological analysis of the Liver Cirrhosis market insight reveals historically significant and forward-looking trends across the 7MM from 2020 to 2034:
- The US recorded approximately 2,070 thousand total diagnosed prevalent cases of liver cirrhosis in 2023, the highest among all 7MM countries, with projections indicating continued growth through 2034
- EU4 and the UK collectively accounted for around 830 thousand diagnosed prevalent cases in 2023, with Germany contributing the highest share within this group
- Japan contributed approximately 14% of total 7MM liver cirrhosis cases, while EU4 and the UK together contributed around 24%
- In Japan, etiology-specific distribution revealed that HCV remains the dominant driver at 45% of cases, followed by ALD at 26%, HBV at 15%, MASH at 13%, and PBC at 2%
Liver Cirrhosis Emerging Drugs
- Efruxifermin (AKR-001) – Akero Therapeutics, Inc.
Efruxifermin (EFX) is Akero Therapeutics’ lead pipeline candidate targeting MASH cirrhosis. Designed for convenient once-weekly subcutaneous dosing, EFX is currently being evaluated in the SYMMETRY Phase IIb clinical trial in patients with biopsy-confirmed compensated F4 fibrosis. The consistency and magnitude of observed effects have positioned EFX as a potentially best-in-class treatment option if approved.
- Belapectin (GR-MD-02) – Galectin Therapeutics Inc.
Belapectin is a proprietary galectin-3 inhibitor with demonstrated preclinical efficacy in reversing liver fibrosis and cirrhosis. Clinical studies have confirmed its capacity to reduce portal hypertension and prevent the development of esophageal varices. Belapectin completed the NASH-CX Phase IIb clinical trial in MASH patients with compensated cirrhosis and portal hypertension – making it the first large randomized clinical trial of any drug to demonstrate clinically meaningful improvement in portal hypertension in NASH cirrhosis patients without varices.
- Zibotentan/Dapagliflozin – AstraZeneca
AstraZeneca’s innovative combination therapy pairs zibotentan, an endothelin A receptor antagonist, with dapagliflozin (Farxiga/Forxiga), an SGLT2 inhibitor. Currently in Phase IIb clinical development via the ZEAL-UNLOCK study – initiated in February 2024 – this combination targets liver cirrhosis through complementary mechanisms and aims to address significant unmet medical needs in this indication.
Recent Developments
- Boehringer Ingelheim, Newcastle University, and the University of Edinburgh launched the landmark ADVANCE study – the most comprehensive observational study of MASH cirrhosis ever undertaken globally
- Akero Therapeutics advanced EFX through the SYMMETRY Phase IIb trial, demonstrating compelling efficacy data in compensated cirrhosis patients
- AstraZeneca initiated the ZEAL-UNLOCK Phase IIb trial evaluating zibotentan/dapagliflozin combination in liver cirrhosis
- Galectin Therapeutics progressed belapectin through two Phase I and multiple Phase II clinical studies targeting advanced MASH fibrosis and compensated cirrhosis
Leading Liver Cirrhosis Companies
The competitive landscape of the Liver Cirrhosis market features an active and growing roster of innovators. Leading companies developing therapies include Madrigal Pharmaceuticals, Galectin Therapeutics, Grifols Therapeutics, CymaBay Therapeutics, Akero Therapeutics, NGM Biopharmaceuticals, Gilead Sciences, Novo Nordisk, Cellaion, Promethera Therapeutics, Lipocine, Bristol Myers Squibb, Prism Pharma, Ohara Pharmaceutical, Shionogi, Rohto, and others.
Conclusion
The global liver cirrhosis landscape is at a pivotal inflection point. With the 7MM market surpassing USD 3,100 million in 2023 and a robust pipeline of emerging therapies advancing through clinical trials, the Liver Cirrhosis market trends signal a period of meaningful transformation ahead. Improved diagnostic tools, novel pharmacological agents, and landmark real-world research initiatives such as the ADVANCE study are collectively reshaping how this chronic disease is understood, detected, and managed. As the forecast period through 2034 unfolds, continued investment in innovation, patient-centric care models, and equitable access to therapy will define the trajectory of the liver cirrhosis treatment market.
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharmaceutical companies by providing comprehensive end-to-end solutions to improve their performance. It also offers healthcare consulting services that leverage market analysis to accelerate business growth and overcome challenges with practical approaches.
Media contact
Name: Abhishek kumar
E-mail:abhishek@delveinsight.com
